精原细胞瘤和胚胎性癌中频繁表达 CD45RO 记忆 T 细胞标志物，以及低至高表达 PD-1 和 PD-L1 抑制分子。

Frequent expression of CD45RO memory T cell marker as well as low to high expression of PD-1 and PD-L1 inhibitory molecules in seminoma and dysgerminoma.

机构信息

Department of Immunology, School of medicine, Shiraz University of Medical sciences, Shiraz, Islamic Republic of Iran; Shiraz Institute for Cancer Research, School of medicine, Shiraz University of Medical sciences, Shiraz, Islamic Republic of Iran.

Pathology Department, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Islamic Republic of Iran.

出版信息

J Reprod Immunol. 2024 Feb;161:104184. doi: 10.1016/j.jri.2023.104184. Epub 2023 Dec 15.

DOI:10.1016/j.jri.2023.104184

PMID:38171036

Abstract

BACKGROUND

Seminoma and dysgerminoma are rare testicular and ovarian germ cell tumors characterized by a significant infiltration of immune cells in the tumor microenvironment. According to the failure of conventional treatments in some patients, it is crucial to identify novel prognostic and therapeutic biomarkers for these patients. The objectives of this study were to evaluate the expression of CD45RO and PD-1/PD-L1 and investigate their association with the clinicopathological characteristics of the patients.

METHODS

Immunohistochemistry was performed to assess the expression of CD45RO, PD-1, and PD-L1 in tumor-infiltrated lymphocytes (TILs), and tumor cells in 33 seminoma and 31 dysgerminoma patients. The expression levels were evaluated using a semiquantitative approach, weighted histoscore, which considers both the intensity and extent of staining.

RESULTS

All seminoma and dysgerminoma patients exhibited CD45RO expression in TILs, with 66.7 % and 90.3 % displaying high levels of expression, respectively. PD-1 expression in TILs was observed at low levels in 81.8 % and 77.4 % and at high levels in 18.2 % and 19.4 % of seminoma and dysgerminoma patients, respectively. Likewise, low expression of PD-L1 in tumor cells was detected in 63.6 % of seminoma and 61.3 % of dysgerminoma patients, while none of the patients exhibited high expression of PD-L1. In seminoma patients, a positive correlation was observed between PD-1 expression in TILs and CD45RO expression and between PD-L1 expression in tumor cells and TILs score.

CONCLUSION

The frequent infiltration of CD45RO, along with variable expression of PD-1 and PD-L1 on TILs and tumor cells, could impact the effectiveness of anti-tumor responses and immunotherapy.

摘要

背景

精原细胞瘤和卵黄囊瘤是罕见的睾丸和卵巢生殖细胞肿瘤，其肿瘤微环境中有大量免疫细胞浸润。根据部分患者常规治疗失败的情况，确定这些患者的新的预后和治疗生物标志物至关重要。本研究的目的是评估 CD45RO 和 PD-1/PD-L1 的表达，并研究其与患者临床病理特征的关系。

方法

对 33 例精原细胞瘤和 31 例卵黄囊瘤患者的肿瘤浸润淋巴细胞（TIL）和肿瘤细胞中 CD45RO、PD-1 和 PD-L1 的表达进行免疫组织化学检测。采用半定量方法评估表达水平，即加权组织评分，同时考虑染色强度和范围。

结果

所有精原细胞瘤和卵黄囊瘤患者的 TIL 均表达 CD45RO，分别有 66.7%和 90.3%表达高水平。TIL 中 PD-1 的表达水平在 81.8%和 77.4%的精原细胞瘤和卵黄囊瘤患者中较低，而在 18.2%和 19.4%的患者中较高。同样，在 63.6%的精原细胞瘤和 61.3%的卵黄囊瘤患者中，肿瘤细胞中 PD-L1 的表达水平较低，而无一例患者 PD-L1 表达水平较高。在精原细胞瘤患者中，TIL 中 PD-1 的表达与 CD45RO 的表达以及肿瘤细胞中 PD-L1 的表达与 TIL 评分之间存在正相关关系。